| pubmed-article:10479169 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C0231220 | lld:lifeskim |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C0205177 | lld:lifeskim |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C0750729 | lld:lifeskim |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C1548602 | lld:lifeskim |
| pubmed-article:10479169 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:10479169 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10479169 | pubmed:dateCreated | 1999-11-8 | lld:pubmed |
| pubmed-article:10479169 | pubmed:abstractText | Highly active antiretroviral treatment (HAART) was given early to 64 patients with symptomatic primary human immunodeficiency virus (HIV)-1 infection. At the time of analysis, patients had been followed up for 9-21 months. No patient had died or developed an AIDS-defining event. Survival analysis showed that by month 21 the proportion of patients with plasma HIV-1 RNA <50 copies/mL was 72% (95% confidence interval, 58%-95%) in intention-to-treat analysis. After 18 months of treatment, 50% of the patients with undetectable plasma HIV-1 RNA also had undetectable HIV-1 RNA in peripheral blood mononuclear cells (PBMC). Only 1 of 3 patients had undetectable HIV-1 RNA in lymphoid tissue, while all patients had quantifiable HIV-1 DNA both in PBMC and lymphoid tissue. The median CD4 lymphocyte increase from baseline was 230 cells/microL. These preliminary results support the use of HAART in patients with primary HIV-1 infection. | lld:pubmed |
| pubmed-article:10479169 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10479169 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10479169 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:10479169 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10479169 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10479169 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10479169 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10479169 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10479169 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10479169 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:10479169 | pubmed:issn | 0022-1899 | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:FleuryHH | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:RagnaudJ MJM | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:RaffiFF | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:SéréniDD | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:HarzicMM | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:VenetAA | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:BeauvaisLL | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:HoenBB | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:BourezaneYY | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:DumonBB | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:Bicart-SeeAA | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:LascouxCC | lld:pubmed |
| pubmed-article:10479169 | pubmed:author | pubmed-author:DubeauxBB | lld:pubmed |
| pubmed-article:10479169 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10479169 | pubmed:volume | 180 | lld:pubmed |
| pubmed-article:10479169 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10479169 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10479169 | pubmed:pagination | 1342-6 | lld:pubmed |
| pubmed-article:10479169 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:meshHeading | pubmed-meshheading:10479169... | lld:pubmed |
| pubmed-article:10479169 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10479169 | pubmed:articleTitle | Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. | lld:pubmed |
| pubmed-article:10479169 | pubmed:affiliation | Service de Maladies Infectieuses et Tropicales, CHU de Besançon-Hôpital Saint-Jacques, F-25030 Besancon Cedex, France. bruno.hoen@univ-fcomte.fr | lld:pubmed |
| pubmed-article:10479169 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10479169 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10479169 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:10479169 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10479169 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10479169 | lld:pubmed |
